Related references
Note: Only part of the references are listed.Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents
Subhasish Baral et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
Vishnu Venugopal et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
Miguel Malespin et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Paul Kwo et al.
GASTROENTEROLOGY (2017)
Response-Guided Duration of Direct Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
Alessio Aghemo et al.
GASTROENTEROLOGY (2017)
Augmentation of hepatitis C virus-specific immunity and sustained virologic response
S. Shrivastava et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations
Pranesh Padmanabhan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
REPLY TO PADMANABHAN AND DIXIT: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments
Hirofumi Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
Yoshiki Koizumi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
Thi Huyen Tram Nguyen et al.
SCIENTIFIC REPORTS (2017)
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents
Ashish Goyal et al.
ANTIVIRAL RESEARCH (2017)
Randomized comparison of daclatasvir plus asunaprevir versus telaprevir plus peginterferon/ribavirin in Japanese hepatitis C virus patients
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial
Gregory J. Dore et al.
ANNALS OF INTERNAL MEDICINE (2016)
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
Paul J. Pockros et al.
GASTROENTEROLOGY (2016)
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
Mark S. Sulkowski et al.
GASTROENTEROLOGY (2016)
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
George N. Ioannou et al.
GASTROENTEROLOGY (2016)
Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study
Paul Kwo et al.
HEPATOLOGY (2016)
Simeprevir Plus Sofosbuvir in Patients With Chronic Hepatitis C Virus Genotype 1 Infection and Cirrhosis: A Phase 3 Study (OPTIMIST-2)
Eric Lawitz et al.
HEPATOLOGY (2016)
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea
Lai Wei et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem et al.
JOURNAL OF HEPATOLOGY (2016)
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens
Benjamin Maasoumy et al.
JOURNAL OF HEPATOLOGY (2016)
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Harel Dahari et al.
JOURNAL OF HEPATOLOGY (2016)
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J. Dore et al.
JOURNAL OF HEPATOLOGY (2016)
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
Matthias Gotte et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
George Lau et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report
Yaakov Hasin et al.
WORLD JOURNAL OF HEPATOLOGY (2016)
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir
R. K. Sterling et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
Dandan Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance
Elizabeth M. Steinert et al.
CELL (2015)
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials
Patrick R. Harrington et al.
CLINICAL INFECTIOUS DISEASES (2015)
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
Sreetha Sidharthan et al.
CLINICAL INFECTIOUS DISEASES (2015)
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
Eric Lawitz et al.
GASTROENTEROLOGY (2015)
Randomized Trial of Interferon- and Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir in Treatment-Experienced Hepatitis C Virus-Infected Patients
Kazuaki Chayama et al.
HEPATOLOGY (2015)
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Erik Lontok et al.
HEPATOLOGY (2015)
Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
Andrew J. Muir et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
Fred Poordad et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4
Christophe Moreno et al.
JOURNAL OF HEPATOLOGY (2015)
ON-TREATMENT VIRAL KINETICS DO NOT PREDICT SVR IN PATIENTS WITH ADVANCED LIVER DISEASE RECEIVING SOFOSBUVIR IN COMBINATION WITH DACLATASVIR OR SIMEPREVIR FOR 12 WEEKS
C. Hezode et al.
JOURNAL OF HEPATOLOGY (2015)
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
Jacob Lalezari et al.
JOURNAL OF HEPATOLOGY (2015)
A signature for immune response correlates with HCV treatment outcome in Caucasian subjects
Brian J. Hare et al.
JOURNAL OF PROTEOMICS (2015)
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy
Christoph Sarrazin et al.
JOURNAL OF VIROLOGICAL METHODS (2015)
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark Sulkowski et al.
LANCET (2015)
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
Anita Kohli et al.
LANCET (2015)
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Eric Lawitz et al.
LANCET (2015)
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
David Roth et al.
LANCET (2015)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami et al.
LANCET INFECTIOUS DISEASES (2015)
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial
K. Rajender Reddy et al.
LANCET INFECTIOUS DISEASES (2015)
Modelling hepatitis C therapy-predicting effects of treatment
Alan S. Perelson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Asma Ahmed et al.
VIRUSES-BASEL (2015)
Successes and Challenges on the Road to Cure Hepatitis C
Stacy M. Horner et al.
PLOS PATHOGENS (2015)
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
Fei Xiao et al.
GUT (2015)
Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
Hiromitsu Kumada et al.
HEPATOLOGY RESEARCH (2015)
Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes
P. Padmanabhan et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
HCV Kinetic Models and Their Implications in Drug Development
T. H. T. Nguyen et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin
Eisuke Murakami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2014)
Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
Stefan Zeuzem et al.
GASTROENTEROLOGY (2014)
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Pietro Andreone et al.
GASTROENTEROLOGY (2014)
Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
Christophe Hezode et al.
GASTROENTEROLOGY (2014)
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
David R. McGivern et al.
GASTROENTEROLOGY (2014)
Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C
Maria Buti et al.
GASTROENTEROLOGY (2014)
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
Yaron Rotman et al.
GUT (2014)
Simultaneous Detection of Hepatitis C Virus and Interferon Stimulated Gene Expression in Infected Human Liver
Stefan Wieland et al.
HEPATOLOGY (2014)
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
Namiki Izumi et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
John M. Vierling et al.
JOURNAL OF HEPATOLOGY (2014)
Restoration of HCV-specific CD8+T cell function by interferon-free therapy
Bianca Martin et al.
JOURNAL OF HEPATOLOGY (2014)
Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
Norio Hayashi et al.
JOURNAL OF HEPATOLOGY (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Ira M. Jacobson et al.
LANCET (2014)
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
Michael Manns et al.
LANCET (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses
Szun Szun Tay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment
Pranesh Padmanabhan et al.
NATURE COMMUNICATIONS (2014)
A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
Jessica M. Conway et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity
Hangfei Qi et al.
PLOS PATHOGENS (2014)
Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin
Eric G. Meissner et al.
OPEN FORUM INFECTIOUS DISEASES (2014)
Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection
Steven L. Flamm et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients With HCV Genotype 1 Infection
Daryl T. -Y. Lau et al.
GASTROENTEROLOGY (2013)
Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Hepatitis C: The Randomized PILLAR Study
Michael W. Fried et al.
HEPATOLOGY (2013)
ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPY
L. Barrett et al.
JOURNAL OF HEPATOLOGY (2013)
Innate immunity and HCV
Markus H. Heim
JOURNAL OF HEPATOLOGY (2013)
Proteome-Wide Measurement of Protein Half-Lives and Translation Rates in Vasopressin-Sensitive Collecting Duct Cells
Pablo C. Sandoval et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
Celia Perales et al.
JOURNAL OF VIROLOGY (2013)
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
Ludmila Prokunina-Olsson et al.
NATURE GENETICS (2013)
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Jeremie Guedj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Elizabeth B. Wilson et al.
SCIENCE (2013)
An Interferon Paradox
Pamela M. Odorizzi et al.
SCIENCE (2013)
Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling
John R. Teijaro et al.
SCIENCE (2013)
A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms
Sheeja M. Krishnan et al.
ANTIVIRAL THERAPY (2012)
Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor
Libin Rong et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2012)
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
Christoph Welsch et al.
GUT (2012)
Identification of Type I and Type II Interferon-Induced Effectors Controlling Hepatitis C Virus Replication
Philippe Metz et al.
HEPATOLOGY (2012)
Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals
Haihong Zhu et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Dynamics of alternative modes of RNA replication for positive-sense RNA viruses
Josep Sardanyes et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2012)
Multi-layered stochasticity and paracrine signal propagation shape the type-I interferon response
Ulfert Rand et al.
MOLECULAR SYSTEMS BIOLOGY (2012)
Genetics of IL28B and HCV-response to infection and treatment
C. Nelson Hayes et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
The specific infectivity of hepatitis C virus changes through its life cycle
Sun Ju Keum et al.
VIROLOGY (2012)
dsRNA-Dependent Protein Kinase PKR and its Role in Stress, Signaling and HCV Infection
Stephanie Dabo et al.
VIRUSES-BASEL (2012)
A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
Bambang S. Adiwijaya et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
Ruy M. Ribeiro et al.
PLOS PATHOGENS (2012)
Failure of innate and adaptive immune responses in controlling hepatitis C virus infection
Robert Thimme et al.
FEMS MICROBIOLOGY REVIEWS (2012)
Dynamics of a Plant RNA Virus Intracellular Accumulation: Stamping Machine vs. Geometric Replication
Fernando Martinez et al.
GENETICS (2011)
Retreatment with Telaprevir Combination Therapy in Hepatitis C Patients with Well-Characterized Prior Treatment Response
Andrew J. Muir et al.
HEPATOLOGY (2011)
The Antiviral Protein Viperin Inhibits Hepatitis C Virus Replication via Interaction With Nonstructural Protein 5A
Karla J. Helbig et al.
HEPATOLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
P. -Y. Bochud et al.
JOURNAL OF HEPATOLOGY (2011)
Systems-wide Proteomic Analysis in Mammalian Cells Reveals Conserved, Functional Protein Turnover
Sidney B. Cambridge et al.
JOURNAL OF PROTEOME RESEARCH (2011)
ISG56 and IFITM1 Proteins Inhibit Hepatitis C Virus Replication
Amit Raychoudhuri et al.
JOURNAL OF VIROLOGY (2011)
Stochastic Receptor Expression Determines Cell Fate upon Interferon Treatment
Doron Levin et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins et al.
NATURE (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry
Pranesh Padmanabhan et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy
Sheeja M. Krishnan et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
E. Snoeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Cleavage of Mitochondrial Antiviral Signaling Protein in the Liver of Patients with Chronic Hepatitis C Correlates with a Reduced Activation of the Endogenous Interferon System
Pantxika Bellecave et al.
HEPATOLOGY (2010)
Inhibition of Hepatitis C Virus Replication by IFN-Mediated ISGylation of HCV-NS5A
Min-Jung Kim et al.
JOURNAL OF IMMUNOLOGY (2010)
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Paul Y. Kwo et al.
LANCET (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Translational insensitivity to potent activation of PKR by HCV IRES RNA
Takashi Shimoike et al.
ANTIVIRAL RESEARCH (2009)
Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation
Urtzi Garaigorta et al.
CELL HOST & MICROBE (2009)
Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon
Harel Dahari et al.
JOURNAL OF VIROLOGY (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Treatment predictors of a sustained virologic response in hepatitis B and C
Annika Kau et al.
JOURNAL OF HEPATOLOGY (2008)
Eukaryotic translation initiation machinery can operate in a bacterial-like mode without eIF2
Ilya M. Terenin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Interferon signaling and treatment outcome in chronic hepatitis C
Magdalena Sarasin-Filipowicz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
Jordan J. Feld et al.
HEPATOLOGY (2007)
Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-α against hepatitis C virus
Wei-Liang Liu et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Triphasic decline of hepatitis C virus RNA during antiviral therapy
Harel Dahari et al.
HEPATOLOGY (2007)
Activation of PKR: an open and shut case?
James L. Cole
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells
Harel Dahari et al.
JOURNAL OF VIROLOGY (2007)
Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States
Omana V. Nainan et al.
GASTROENTEROLOGY (2006)
Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms
Guofeng Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The interferon response circuit: Induction and suppression by pathogenic viruses
O Haller et al.
VIROLOGY (2006)
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies
JM Micallef et al.
JOURNAL OF VIRAL HEPATITIS (2006)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci et al.
JOURNAL OF HEPATOLOGY (2005)
eIF2 and the control of cell physiology
CG Proud
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
NM Dixit et al.
NATURE (2004)
Dynamics of alanine aminotransferase during hepatitis C virus treatment
RM Ribeiro et al.
HEPATOLOGY (2003)
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline
JE Layden et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Hepatitis C virus IRES-dependent translation is insensitive to an eIF2α-independent mechanism of inhibition by interferon in hepatocyte cell lines
G Koev et al.
VIROLOGY (2002)
Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA
JQ Han et al.
RNA (2002)
Bistability in cell signaling: How to make continuous processes discontinuous, and reversible processes irreversible
JE Ferrell et al.
CHAOS (2001)
Share Paper
